GLP-1 and Addictions: What Science Knows So Far

People taking GLP-1s report losing interest in alcohol, smoking less, feeling less driven by urges that once ruled their lives. 

It caught my attention. So I went straight to the research to separate solid science from clickbait headlines and what I found was even more compelling than I expected.

Understanding the Mechanism

The secret lies in how GLP-1 agonists interact with our brain's reward circuitry. Unlike other addiction treatments that often target specific substances, GLP-1 receptors are strategically positioned throughout the brain, particularly in areas that regulate dopamine that crucial neurotransmitter driving our motivation and pleasure-seeking behaviors.

When we engage in destructive habits, whether it's drinking alcohol or gambling, our brains flood with dopamine, creating that powerful cycle of craving and reinforcement we know all too well. GLP-1 medications appear to act like a volume dial, turning down this dopamine response and making previously irresistible behaviors feel surprisingly manageable.

Anecdotal reports first hinted at this effect: people on weight loss meds casually noted they’d lost interest in wine or no longer felt the urge to smoke.

Now, large-scale scientific data is confirming these stories.

"

Researchers found that around 21% of GLP-1 users reported a significant reduction in impulsive shopping. They described a shift from spontaneous, emotional purchases to more controlled and planned spending habits.

People report fundamental shifts in purchasing decision-making processes, including enhanced impulse control, increased awareness of financial consequences and more structured approach to consumption.

For gambling, direct clinical studies are few. But because compulsive shopping and gambling share brain pathways, early evidence hints that these drugs could reduce the reward gamblers feel. Patient stories show that lowering dopamine in the brain's reward centers can cut down compulsive behaviors.

Alcohol Use Disorder: The Most Promising Results

The most compelling evidence to date comes from the fight against alcohol use disorder (AUD).

A massive registry study of over 227,000 individuals with AUD found that people using semaglutide had a 36% reduction in alcohol-related hospitalizations compared to periods when they weren't on the medication.

Perhaps most remarkably, a study of over 14,000 people seeking weight loss found that 45.3% reported decreased alcohol consumption as an unexpected bonus.

Opioid Use Disorder: Emerging Promise

The opioid crisis has devastated communities for decades. A landmark study of over 500,000 individuals with opioid use disorder (OUD) delivered a stunning finding: those taking GLP-1 medications had a 40% lower risk of overdose.

What makes this so significant is that GLP-1s have no addiction potential themselves. Unlike replacement therapies, they don't substitute one dependency for another. Instead, they appear to directly address the underlying cravings that lead to relapse and overdose.

Nicotine and Other Substances

The evidence for treating nicotine, cocaine, cannabis and stimulant addiction with GLP-1s is mixed. Social media analyses reveal about 23% of users say they've used less cannabis after starting treatment, but the results vary and aren't yet consistent.

Interesting: Addiction Transfer Phenomena

We're still early in understanding this, but some people report a curious switch: GLP-1s helped them quit drinking only to spark new habits like overspending. One behavior quiets down, and another starts whispering.

It suggests GLP-1s might mute the reward signal for a specific addiction, but they don't always touch the root causes - stress, anxiety, boredom. If that core need isn't addressed, the brain just finds a new outlet. Different vice, same itch.

We're seeing early signs of a possible shift in how we treat addiction. What hits me most is how it all started. People were just trying to lose weight, then noticed their cravings fading. That sparked more studies, and the results keep coming.

The idea that one kind of drug could ease different addictions by calming the brain’s reward system is promising. Quietly, it’s reshaping what we know about GLP-1s.

If you find this post useful, copy the link and share it with someone else walking the GLP-1 path. Every new reader who joins our email list makes a difference.